| Pregnancy |
1 |
1 |
| Abortion |
0 |
0.99 |
| Spontaneous Abortion |
0 |
0.69 |
| Contraception |
0 |
0.24 |
| Congenital Anomaly |
0 |
0.19 |
| Sterilization, Birth Control |
0 |
0.98 |
| Birth |
0 |
0.18 |
| Acne |
0 |
0.14 |
| Clinical Research |
0 |
0.13 |
| Rosacea |
0 |
0.12 |
| Dermatitis |
0 |
0.11 |
| Healthcare and Medical Technology |
0 |
0.11 |
| Chronic Disease |
0 |
0.09 |
| Isotretinoin |
0 |
0.09 |
| Michigan |
0 |
0.09 |
| Adverse Effects |
0 |
0.07 |
| California |
0 |
0.07 |
| Child |
0 |
0.07 |
| Patient Safety |
0 |
0.07 |
| Psoriasis |
0 |
0.07 |
| Adherence |
0 |
0.04 |
| Atopic Dermatitis |
0 |
0.04 |
| Kentucky |
0 |
0.04 |
| Lupus |
0 |
0.04 |
| Mississippi |
0 |
0.04 |
| Residency |
0 |
0.04 |
| Skin and Soft Tissue Infection |
0 |
0.04 |
| Biologic Therapy |
0 |
0.03 |
| Rheumatoid Arthritis |
0 |
0.03 |
| Antiviral Agents |
0 |
0.02 |
| Arizona |
0 |
0.02 |
| Arthritis |
0 |
0.02 |
| Cancer |
0 |
0.02 |
| Florida |
0 |
0.02 |
| Hand |
0 |
0.02 |
| High-Risk Pregnancy |
0 |
0.02 |
| Idaho |
0 |
0.02 |
| Immunology |
0 |
0.02 |
| Immunomodulator |
0 |
0.02 |
| Intrauterine Device |
0 |
0.02 |
| Medical Life |
0 |
0.02 |
| Oklahoma |
0 |
0.02 |
| Physiology |
0 |
0.02 |
| Plaque Psoriasis |
0 |
0.02 |
| Quality of Life |
0 |
0.02 |
| Reproductive Health |
0 |
0.02 |
| Revenue and Practice Management |
0 |
0.02 |
| Risk Evaluation and Mitigation Strategies |
0 |
0.02 |
| South Dakota |
0 |
0.02 |
| Texas |
0 |
0.02 |
| Translational Research |
0 |
0.02 |
| Tubal Ligation |
0 |
0.02 |
| Women in Medicine |
0 |
0.02 |
| Wyoming |
0 |
0.02 |